Phase I and II study of a new bleomycin analog (pepleomycin).
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D017663:Peplomycin
D000970:Antineoplastic Agents; D001761:Bleomycin; D017663:Peplomycin